{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T22:36:18Z","timestamp":1785537378773,"version":"3.56.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T00:00:00Z","timestamp":1600992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T00:00:00Z","timestamp":1600992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>To investigate the incidence of active tuberculosis (TB) among COPD patients using fluticasone\/salmeterol or budesonide\/formoterol, and to identify any differences between these two groups of patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The study enrolled COPD patients from Taiwan NHIRD who received treatment with fluticasone\/salmeterol or budesonide\/formoterol for &gt;\u200990\u2009days between 2004 and 2011. The incidence of active TB was the primary outcome.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among the intention-to-treat population prior to matching, the incidence rates of active TB were 0.94 and 0.61% in the fluticasone\/salmeterol and budesonide\/formoterol groups, respectively. After matching, the fluticasone\/salmeterol group had significantly higher rates of active TB (adjusted HR, 1.41, 95% CI, 1.17\u20131.70) compared with the budesonide\/formoterol group. The significant difference between these two groups remained after a competing risk analysis (HR, 1.45, 95% CI, 1.21\u20131.74). Following propensity score matching, the fluticasone\/salmeterol group had significantly higher rates of active TB compared with the budesonide\/formoterol group (adjusted HR, 1.45, 95% CI, 1.14\u20131.85). A similar trend was observed after a competing risk analysis (HR, 1.44, 95% CI, 1.19\u20131.75). A higher risk of active TB was observed in the fluticasone\/salmeterol group compared with the budesonide\/formoterol group across all subgroups, but some differences did not reach statistical significance.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Fluticasone\/salmeterol carried a higher risk of active TB compared with budesonide\/formoterol among COPD patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-020-05440-6","type":"journal-article","created":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T13:04:16Z","timestamp":1601039056000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Risk of active tuberculosis among COPD patients treated with fixed combinations of long-acting beta2 agonists and inhaled corticosteroids"],"prefix":"10.1186","volume":"20","author":[{"given":"Tsan-Ming","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan-Chih","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6334-2388","authenticated-orcid":false,"given":"Chih-Cheng","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Chien","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Likwang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong-Jen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"On the behalf of Taiwan Clinical Trial Consortium for Respiratory Diseases (TCORE)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong-Jen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Chien","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diahn-Warng","family":"Perng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Lung","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeng-Yuan","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wu-Huei","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeng-Yuan","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wu-Huei","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Huang","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzuen-Ren","family":"Hsiue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Chih","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hen-I","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeun-Chung","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ueng-Cheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cing-Syong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Likwang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Feng","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inn-Wen","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,25]]},"reference":[{"issue":"7","key":"5440_CR1","doi-asserted-by":"publisher","first-page":"797","DOI":"10.5588\/ijtld.18.0757","volume":"23","author":"LR Armstrong","year":"2019","unstructured":"Armstrong LR, Winston CA, Stewart B, Tsang CA, Langer AJ, Navin TR. Changes in tuberculosis epidemiology, United States, 1993-2017. Int J Tuberc Lung Dis. 2019;23(7):797\u2013804.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"2","key":"5440_CR2","doi-asserted-by":"publisher","first-page":"211","DOI":"10.32394\/pe.73.20","volume":"73","author":"M Korzeniewska Kosela","year":"2019","unstructured":"Korzeniewska Kosela M. Tuberculosis in Poland in 2017. Przegl Epidemiol. 2019;73(2):211\u201326.","journal-title":"Przegl Epidemiol"},{"issue":"1","key":"5440_CR3","doi-asserted-by":"crossref","first-page":"7832","DOI":"10.1038\/s41598-017-07959-2","volume":"7","author":"B Wu","year":"2017","unstructured":"Wu B, Yu Y, Xie W, Liu Y, Zhang Y, Hu D, et al. Epidemiology of tuberculosis in Chongqing, China: a secular trend from 1992 to 2015. Sci Rep. 2017;7(1):7832.","journal-title":"Sci Rep"},{"issue":"1","key":"5440_CR4","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12992-019-0461-2","volume":"15","author":"CW Lu","year":"2019","unstructured":"Lu CW, Lee YH, Pan YH, Chang HH, Wu YC, Sheng WH, et al. Tuberculosis among migrant workers in Taiwan. Glob Health. 2019;15(1):18.","journal-title":"Glob Health"},{"issue":"2\u20133","key":"5440_CR5","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.pneumo.2014.04.002","volume":"71","author":"M Mjid","year":"2015","unstructured":"Mjid M, Cherif J, Ben Salah N, Toujani S, Ouahchi Y, Zakhama H, et al. Epidemiology of tuberculosis. Rev Pneumol Clin. 2015;71(2\u20133):67\u201372.","journal-title":"Rev Pneumol Clin"},{"issue":"4","key":"5440_CR6","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S2213-2600(18)30057-2","volume":"6","author":"K Floyd","year":"2018","unstructured":"Floyd K, Glaziou P, Zumla A, Raviglione M. The global tuberculosis epidemic and progress in care, prevention, and research: an overview in year 3 of the end TB era. Lancet Respir Med. 2018;6(4):299\u2013314.","journal-title":"Lancet Respir Med"},{"issue":"7","key":"5440_CR7","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1093\/cid\/ciw376","volume":"63","author":"P Nahid","year":"2016","unstructured":"Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, et al. Official American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016;63(7):e147\u2013e95.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"5440_CR8","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.rppnen.2017.11.003","volume":"24","author":"R Duarte","year":"2018","unstructured":"Duarte R, Lonnroth K, Carvalho C, Lima F, Carvalho ACC, Munoz-Torrico M, et al. Tuberculosis, social determinants and co-morbidities (including HIV). Pulmonology. 2018;24(2):115\u20139.","journal-title":"Pulmonology."},{"key":"5440_CR9","doi-asserted-by":"crossref","unstructured":"Imtiaz S, Shield KD, Roerecke M, Samokhvalov AV, Lonnroth K, Rehm J. Alcohol consumption as a risk factor for tuberculosis: meta-analyses and burden of disease. Eur Respir J. 2017;50(1).","DOI":"10.1183\/13993003.00216-2017"},{"key":"5440_CR10","doi-asserted-by":"crossref","unstructured":"Restrepo BI. Diabetes and tuberculosis. Microbiol Spectr. 2016;4(6).","DOI":"10.1128\/microbiolspec.TNMI7-0023-2016"},{"issue":"4","key":"5440_CR11","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.jaip.2018.10.007","volume":"7","author":"CM Lee","year":"2019","unstructured":"Lee CM, Heo J, Han SS, Moon KW, Lee SH, Kim YJ, et al. Inhaled corticosteroid-related tuberculosis in the real world among patients with asthma and COPD: a 10-year Nationwide population-based study. J Allergy Clin Immunol Pract. 2019;7(4):1197\u2013206.e3.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"8","key":"5440_CR12","doi-asserted-by":"crossref","first-page":"936","DOI":"10.5588\/ijtld.15.0031","volume":"19","author":"CC Lai","year":"2015","unstructured":"Lai CC, Lee MT, Lee SH, Lee SH, Chang SS, Lee CC. Risk of incident active tuberculosis and use of corticosteroids. Int J Tuberc Lung Dis. 2015;19(8):936\u201342.","journal-title":"Int J Tuberc Lung Dis"},{"key":"5440_CR13","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ejim.2017.05.020","volume":"43","author":"SW Lai","year":"2017","unstructured":"Lai SW, Lin CL, Liao KF. Nation-based case-control study investigating the relationship between oral corticosteroids use and pulmonary tuberculosis. Eur J Intern Med. 2017;43:53\u20137.","journal-title":"Eur J Intern Med"},{"key":"5440_CR14","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1378\/chest.13-2137","volume":"145","author":"YH Dong","year":"2014","unstructured":"Dong YH, Chang CH, Wu FL, Shen LJ, Calverley P, L\u00f6fdahl CG, et al. Use of inhaled corticosteroids in patients with COPD and the risk of TB and influenza: a systematic review and meta-analysis of randomized controlled trials a systematic review and meta-analysis of randomized controlled trials. Chest. 2014;145:1286\u201397.","journal-title":"Chest"},{"key":"5440_CR15","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.2147\/COPD.S20927316","volume":"14","author":"G Castellana","year":"2019","unstructured":"Castellana G, Castellana M, Castellana C, Castellana G, Resta E, Carone M, et al. Inhaled corticosteroids and risk of tuberculosis in patients with obstructive lung disease: a systematic review and meta-analysis of non-randomized studies. Int J Chron Obstruct Pulmon Dis. 2019;14:2219\u201327. https:\/\/doi.org\/10.2147\/COPD.S20927316.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"5","key":"5440_CR16","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1164\/rccm.201701-0218PP","volume":"195","author":"CF Vogelmeier","year":"2017","unstructured":"Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am J Respir Crit Care Med. 2017;195(5):557\u201382.","journal-title":"Am J Respir Crit Care Med"},{"issue":"9356","key":"5440_CR17","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(03)12459-2","volume":"361","author":"P Calverley","year":"2003","unstructured":"Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003;361(9356):449\u201356.","journal-title":"Lancet."},{"issue":"8","key":"5440_CR18","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMoa063070","volume":"356","author":"PM Calverley","year":"2007","unstructured":"Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775\u201389.","journal-title":"N Engl J Med"},{"key":"5440_CR19","doi-asserted-by":"crossref","first-page":"f3306","DOI":"10.1136\/bmj.f3306","volume":"346","author":"C Janson","year":"2013","unstructured":"Janson C, Larsson K, Lisspers KH, Stallberg B, Stratelis G, Goike H, et al. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting beta2 agonist: observational matched cohort study (PATHOS). BMJ. 2013;346:f3306.","journal-title":"BMJ"},{"key":"5440_CR20","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.2147\/COPD.S116750","volume":"11","author":"CY Wang","year":"2016","unstructured":"Wang CY, Lai CC, Yang WC, Lin CC, Chen L, Wang HC, et al. The association between inhaled corticosteroid and pneumonia in COPD patients: the improvement of patients' life quality with COPD in Taiwan (IMPACT) study. Int J Chron Obstruct Pulmon Dis. 2016;11:2775\u201383.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"17","key":"5440_CR21","doi-asserted-by":"crossref","first-page":"6863","DOI":"10.18632\/aging.102217","volume":"11","author":"CYLY Wang","year":"2019","unstructured":"Wang CYLY, Wang YH, Lai CC, Wang HC, Chen L, YU CJ. Risk of sepsis among patients with COPD treated with fixed combinations of inhaled corticosteroids and long-acting Beta2 agonists. Aging. 2019;11(17):6863\u201371.","journal-title":"Aging."},{"issue":"5","key":"5440_CR22","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1164\/rccm.200904-0549OC","volume":"180","author":"HH Lin","year":"2009","unstructured":"Lin HH, Ezzati M, Chang HY, Murray M. Association between tobacco smoking and active tuberculosis in Taiwan: prospective cohort study. Am J Respir Crit Care Med. 2009;180(5):475\u201380.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"5440_CR23","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1046\/j.0306-5251.2001.01493.x","volume":"52","author":"L Thorsson","year":"2001","unstructured":"Thorsson L, Edsbacker S, Kallen A, Lofdahl CG. Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler. Br J Clin Pharmacol. 2001;52(5):529\u201338.","journal-title":"Br J Clin Pharmacol"},{"key":"5440_CR24","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/1465-9921-10-104","volume":"10","author":"C Dalby","year":"2009","unstructured":"Dalby C, Polanowski T, Larsson T, Borgstrom L, Edsbacker S, Harrison TW. The bioavailability and airway clearance of the steroid component of budesonide\/formoterol and salmeterol\/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. Respir Res. 2009;10:104.","journal-title":"Respir Res"},{"issue":"7","key":"5440_CR25","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1034\/j.1398-9995.1999.00087.x","volume":"54","author":"A Ek","year":"1999","unstructured":"Ek A, Larsson K, Siljerud S, Palmberg L. Fluticasone and budesonide inhibit cytokine release in human lung epithelial cells and alveolar macrophages. Allergy. 1999;54(7):691\u20139.","journal-title":"Allergy."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05440-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-020-05440-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05440-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T23:11:32Z","timestamp":1632525092000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-020-05440-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,25]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["5440"],"URL":"https:\/\/doi.org\/10.1186\/s12879-020-05440-6","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,25]]},"assertion":[{"value":"10 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Because the records of patients have been anonymized and de-identified, no informed consent was required. Ethical approval was obtained from the Institutional Review Board of Cardinal Tien hospital (No. CTH 108\u20133\u20135-013).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"706"}}